Neal Walker Aclaris Therapeutics, Inc. (ACRS) insider trading activity

Neal Walker is INTERIM CEO of Aclaris Therapeutics, Inc.. Currently has a direct ownership of 1.45 Million shares of ACRS, which is worth approximately $3.59 Million. The most recent transaction as insider was on Jan 02, 2025, when has been sold 13,532 shares (Common Stock) at a price of $2.48 per share, resulting in proceeds of $33,559. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.45M

6.22% 3M change

14.26% 12M change

Total Value Held $3.59 Million

Neal Walker Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2025	SELL Payment of exercise price or tax liability	$33,559 $2.48 p/Share	13,532 Reduced 0.92%	1,454,810 Common Stock
Jan 02 2025	BUY Exercise of conversion of derivative security	-	29,149 Added 1.95%	1,468,342 Common Stock
Jan 01 2025	SELL Payment of exercise price or tax liability	$9,681 $2.48 p/Share	3,904 Reduced 0.27%	1,439,193 Common Stock
Jan 01 2025	BUY Exercise of conversion of derivative security	-	9,467 Added 0.65%	1,443,097 Common Stock
Dec 04 2024	SELL Payment of exercise price or tax liability	$256,969 $3.76 p/Share	68,343 Reduced 4.55%	1,433,630 Common Stock
Dec 04 2024	BUY Exercise of conversion of derivative security	$180,636 $1.52 p/Share	118,840 Added 7.33%	1,501,973 Common Stock
Dec 01 2024	SELL Payment of exercise price or tax liability	$11,074 $4.07 p/Share	2,721 Reduced 0.2%	1,383,133 Common Stock
Dec 01 2024	BUY Exercise of conversion of derivative security	-	9,466 Added 0.68%	1,385,854 Common Stock
Nov 01 2024	SELL Payment of exercise price or tax liability	$5,686 $2.09 p/Share	2,721 Reduced 0.2%	1,376,388 Common Stock
Nov 01 2024	BUY Exercise of conversion of derivative security	-	9,467 Added 0.68%	1,379,109 Common Stock
Oct 01 2024	SELL Payment of exercise price or tax liability	$3,211 $1.18 p/Share	2,722 Reduced 0.2%	1,369,642 Common Stock
Oct 01 2024	BUY Exercise of conversion of derivative security	-	9,467 Added 0.69%	1,372,364 Common Stock
Sep 01 2024	SELL Payment of exercise price or tax liability	$3,211 $1.18 p/Share	2,722 Reduced 0.2%	1,362,897 Common Stock
Sep 01 2024	BUY Exercise of conversion of derivative security	-	9,466 Added 0.69%	1,365,619 Common Stock
Aug 09 2024	BUY Exercise of conversion of derivative security	$31,354 $0.72 p/Share	43,548 Added 3.11%	1,356,153 Common Stock
Aug 01 2024	SELL Payment of exercise price or tax liability	$3,593 $1.32 p/Share	2,722 Reduced 0.21%	1,312,605 Common Stock
Aug 01 2024	BUY Exercise of conversion of derivative security	-	9,467 Added 0.71%	1,315,327 Common Stock
Jul 01 2024	SELL Payment of exercise price or tax liability	$3,130 $1.15 p/Share	2,722 Reduced 0.21%	1,305,860 Common Stock
Jul 01 2024	BUY Exercise of conversion of derivative security	-	9,467 Added 0.72%	1,308,582 Common Stock
Jun 01 2024	SELL Payment of exercise price or tax liability	$2,803 $1.03 p/Share	2,722 Reduced 0.21%	1,299,115 Common Stock
Jun 01 2024	BUY Exercise of conversion of derivative security	-	9,466 Added 0.72%	1,301,837 Common Stock
May 01 2024	SELL Payment of exercise price or tax liability	$3,507 $1.26 p/Share	2,784 Reduced 0.21%	1,292,371 Common Stock
May 01 2024	BUY Exercise of conversion of derivative security	-	9,467 Added 0.73%	1,295,155 Common Stock
Apr 01 2024	SELL Payment of exercise price or tax liability	$4,062 $1.26 p/Share	3,224 Reduced 0.25%	1,285,688 Common Stock
Apr 01 2024	BUY Exercise of conversion of derivative security	-	9,467 Added 0.73%	1,288,912 Common Stock

Also insider at

ALDX

Aldeyra Therapeutics, Inc. Healthcare

Neal Walker

INTERIM CEO

Wayne, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Value

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aclaris Therapeutics, Inc.

Track Activities on ACRS

Account